COMP <GO>
TGTX vs ARWR // RETURN ON INVESTED CAPITAL (ROIC)
TG Therapeutics Inc. (NASDAQ) VS. Arrowhead Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: TGTX 8
— ARWR 4
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: TGTX
LAST: $59.95 (-2.01%) • MKT CAP: $9.36B
roic
12.00%
LAST: $59.57 (-0.55%) • MKT CAP: $8.46B
roic
11.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TGTX VS. ARWR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TGTX | ARWR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 12.00% | 11.10% | +0.90 | TGTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.3x | 73.8x | -0.50 | TGTX | /valuation <GO> |
| Free Cash Flow Yield | -0.28% | 1.84% | -2.12 | ARWR | /fcf-yield <GO> |
| Operating Margin | 20.00% | 11.90% | +8.10 | TGTX | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -0.20% | +68.20 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 87.30% | 180.00% | -92.70 | ARWR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.92 | 6.60 | +6.32 | TGTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | ARWR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.7 | 41.3 | +23.40 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.96 | -0.09 | ARWR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.7x | 18.0x | -1.30 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.36B | $8.46B | $903.6M | TGTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TGTX REV | ARWR REV | TGTX GROSS % | ARWR GROSS % | TGTX FCF | ARWR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | $829.4M | 83.7% | — | -$25.0M | $156.9M |
| FY 2024 | $329.0M | $3.6M | 88.3% | — | -$40.6M | -$604.3M |
| FY 2023 | $233.7M | $240.7M | — | — | -$41.9M | -$164.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TGTX // BETA 0.87
ARWR // BETA 0.96